Skip to main content
Erschienen in: NeuroMolecular Medicine 2/2011

01.06.2011 | Original Paper

Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility

verfasst von: Niklas Mattsson, Shahrzad Tabatabaei, Per Johansson, Oskar Hansson, Ulf Andreasson, Jan-Eric Månsson, Jan-Ove Johansson, Bob Olsson, Anders Wallin, Johan Svensson, Kaj Blennow, Henrik Zetterberg

Erschienen in: NeuroMolecular Medicine | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Activated microglial cells, which are the resident macrophages of the central nervous system, surround amyloid β-plaques in Alzheimer’s disease (AD) brains. Inflammation including microglial activation may contribute in AD pathogenesis, and biomarkers for this process may thus be of value to study AD pathogenesis and might facilitate development of therapies targeting these cells. We therefore examined cerebrospinal fluid (CSF) biomarkers in patients with AD, other dementias, mild cognitive impairment and in healthy controls. Samples were analyzed for markers with known association to macrophage activity, including chitotriosidase, YKL-40 (CHI3L1, HC gp-39) and chemokine CC motif ligand 2 (CCL2, MCP1). Patients with AD had higher chitotriosidase activity than controls and patients with stable mild cognitive impairment, consistent with the presence of activated microglial cells in AD brains, but with large overlaps between groups. CCL2 and YKL-40 concentrations did not differ among groups. Microglial markers are unlikely to be useful for AD diagnosis, but might be useful for identification of distinct subgroups of patients, and for the development and implementation of drugs targeting microglial pathology.
Literatur
Zurück zum Zitat Aerts, J. M., van Breemen, M. J., Bussink, A. P., Ghauharali, K., Sprenger, R., Boot, R. G., et al. (2008). Biomarkers for lysosomal storage disorders: Identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatrica. Supplement, 97, 7–14.PubMedCrossRef Aerts, J. M., van Breemen, M. J., Bussink, A. P., Ghauharali, K., Sprenger, R., Boot, R. G., et al. (2008). Biomarkers for lysosomal storage disorders: Identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatrica. Supplement, 97, 7–14.PubMedCrossRef
Zurück zum Zitat American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders, third edition, revised. Arlington, VA, USA: American Psychiatric Association. American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders, third edition, revised. Arlington, VA, USA: American Psychiatric Association.
Zurück zum Zitat Amor, S., Puentes, F., Baker, D., & van der Valk, P. (2010). Inflammation in neurodegenerative diseases. Immunology, 129, 154–169.PubMedCrossRef Amor, S., Puentes, F., Baker, D., & van der Valk, P. (2010). Inflammation in neurodegenerative diseases. Immunology, 129, 154–169.PubMedCrossRef
Zurück zum Zitat Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., et al. (2000). The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain, 123(Pt 11), 2321–2337.PubMedCrossRef Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., et al. (2000). The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain, 123(Pt 11), 2321–2337.PubMedCrossRef
Zurück zum Zitat Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsater, H., Anckarsater, R., et al. (2010). Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. International Journal of Alzheimer’s Disease. Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsater, H., Anckarsater, R., et al. (2010). Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. International Journal of Alzheimer’s Disease.
Zurück zum Zitat Blasko, I., Lederer, W., Oberbauer, H., Walch, T., Kemmler, G., Hinterhuber, H., et al. (2006). Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dementia and Geriatric Cognitive Disorders, 21, 9–15.PubMedCrossRef Blasko, I., Lederer, W., Oberbauer, H., Walch, T., Kemmler, G., Hinterhuber, H., et al. (2006). Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dementia and Geriatric Cognitive Disorders, 21, 9–15.PubMedCrossRef
Zurück zum Zitat Blennow, K., de Leon, M. J., & Zetterberg, H. (2006). Alzheimer’s disease. Lancet, 368, 387–403.PubMedCrossRef Blennow, K., de Leon, M. J., & Zetterberg, H. (2006). Alzheimer’s disease. Lancet, 368, 387–403.PubMedCrossRef
Zurück zum Zitat Boot, R. G., Renkema, G. H., Verhoek, M., Strijland, A., Bliek, J., de Meulemeester, T. M., et al. (1998). The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem, 273, 25680–25685.PubMedCrossRef Boot, R. G., Renkema, G. H., Verhoek, M., Strijland, A., Bliek, J., de Meulemeester, T. M., et al. (1998). The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem, 273, 25680–25685.PubMedCrossRef
Zurück zum Zitat Boot, R. G., Verhoek, M., de Fost, M., Hollak, C. E., Maas, M., Bleijlevens, B., et al. (2004). Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood, 103, 33–39.PubMedCrossRef Boot, R. G., Verhoek, M., de Fost, M., Hollak, C. E., Maas, M., Bleijlevens, B., et al. (2004). Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood, 103, 33–39.PubMedCrossRef
Zurück zum Zitat Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., et al. (2010). YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biological Psychiatry, 68, 903–912.PubMedCrossRef Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., et al. (2010). YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biological Psychiatry, 68, 903–912.PubMedCrossRef
Zurück zum Zitat Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009). Monocyte chemoattractant protein-1 (MCP-1): An overview. Journal of Interferon and Cytokine Research, 29, 313–326.PubMedCrossRef Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009). Monocyte chemoattractant protein-1 (MCP-1): An overview. Journal of Interferon and Cytokine Research, 29, 313–326.PubMedCrossRef
Zurück zum Zitat Di Rosa, M., Dell’Ombra, N., Zambito, A. M., Malaguarnera, M., Nicoletti, F., & Malaguarnera, L. (2006). Chitotriosidase and inflammatory mediator levels in Alzheimer’s disease and cerebrovascular dementia. European Journal of Neuroscience, 23, 2648–2656.PubMedCrossRef Di Rosa, M., Dell’Ombra, N., Zambito, A. M., Malaguarnera, M., Nicoletti, F., & Malaguarnera, L. (2006). Chitotriosidase and inflammatory mediator levels in Alzheimer’s disease and cerebrovascular dementia. European Journal of Neuroscience, 23, 2648–2656.PubMedCrossRef
Zurück zum Zitat Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., Dekosky, S. T., Barberger-Gateau, P., et al. (2010). Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurology, 9, 1118–1127.PubMedCrossRef Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., Dekosky, S. T., Barberger-Gateau, P., et al. (2010). Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurology, 9, 1118–1127.PubMedCrossRef
Zurück zum Zitat Erkinjuntti, T., Inzitari, D., Pantoni, L., Wallin, A., Scheltens, P., Rockwood, K., et al. (2000). Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission. Supplementum, 59, 23–30.PubMed Erkinjuntti, T., Inzitari, D., Pantoni, L., Wallin, A., Scheltens, P., Rockwood, K., et al. (2000). Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission. Supplementum, 59, 23–30.PubMed
Zurück zum Zitat Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., et al. (2008). PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging, 29, 1456–1465.PubMedCrossRef Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., et al. (2008). PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging, 29, 1456–1465.PubMedCrossRef
Zurück zum Zitat Galasko, D., & Montine, T. J. (2010). Biomarkers of oxidative damage and inflammation in Alzheimer’s disease. Biomarkers in Medicine, 4, 27–36.PubMedCrossRef Galasko, D., & Montine, T. J. (2010). Biomarkers of oxidative damage and inflammation in Alzheimer’s disease. Biomarkers in Medicine, 4, 27–36.PubMedCrossRef
Zurück zum Zitat Galimberti, D., Schoonenboom, N., Scarpini, E., & Scheltens, P. (2003). Chemokines in serum and cerebrospinal fluid of Alzheimer’s disease patients. Annals of Neurology, 53, 547–548.PubMedCrossRef Galimberti, D., Schoonenboom, N., Scarpini, E., & Scheltens, P. (2003). Chemokines in serum and cerebrospinal fluid of Alzheimer’s disease patients. Annals of Neurology, 53, 547–548.PubMedCrossRef
Zurück zum Zitat Hakala, B. E., White, C., & Recklies, A. D. (1993). Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. Journal of Biological Chemistry, 268, 25803–25810.PubMed Hakala, B. E., White, C., & Recklies, A. D. (1993). Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. Journal of Biological Chemistry, 268, 25803–25810.PubMed
Zurück zum Zitat Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006). Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurology, 5, 228–234.PubMedCrossRef Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006). Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurology, 5, 228–234.PubMedCrossRef
Zurück zum Zitat Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994). Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Journal of Clinical Investigation, 93, 1288–1292.PubMedCrossRef Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994). Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Journal of Clinical Investigation, 93, 1288–1292.PubMedCrossRef
Zurück zum Zitat Johansson, P., Mattsson, N., Hansson, O., Wallin, A., Johansson, J. O., Andreasson, U., et al. (2011). Cerebrospinal fluid biomarkers for Alzheimer’s disease: Diagnostic performance in a homogeneous mono-center population. Journal of Alzheimer’s Disease. Johansson, P., Mattsson, N., Hansson, O., Wallin, A., Johansson, J. O., Andreasson, U., et al. (2011). Cerebrospinal fluid biomarkers for Alzheimer’s disease: Diagnostic performance in a homogeneous mono-center population. Journal of Alzheimer’s Disease.
Zurück zum Zitat Lucin, K. M., & Wyss-Coray, T. (2009). Immune activation in brain aging and neurodegeneration: Too much or too little? Neuron, 64, 110–122.PubMedCrossRef Lucin, K. M., & Wyss-Coray, T. (2009). Immune activation in brain aging and neurodegeneration: Too much or too little? Neuron, 64, 110–122.PubMedCrossRef
Zurück zum Zitat Lue, L. F., Rydel, R., Brigham, E. F., Yang, L. B., Hampel, H., Murphy, G. M., Jr., et al. (2001). Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microglia in vitro. Glia, 35, 72–79.PubMedCrossRef Lue, L. F., Rydel, R., Brigham, E. F., Yang, L. B., Hampel, H., Murphy, G. M., Jr., et al. (2001). Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microglia in vitro. Glia, 35, 72–79.PubMedCrossRef
Zurück zum Zitat Luo, X. G., Ding, J. Q., & Chen, S. D. (2010). Microglia in the aging brain: Relevance to neurodegeneration. Molecular Neurodegeneration, 5, 12.PubMedCrossRef Luo, X. G., Ding, J. Q., & Chen, S. D. (2010). Microglia in the aging brain: Relevance to neurodegeneration. Molecular Neurodegeneration, 5, 12.PubMedCrossRef
Zurück zum Zitat Mattsson, N., Blennow, K., & Zetterberg, H. (2010a). Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer’s disease: United we stand, divided we fall. Clinical Chemistry and Laboratory Medicine, 48, 603–607.PubMedCrossRef Mattsson, N., Blennow, K., & Zetterberg, H. (2010a). Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer’s disease: United we stand, divided we fall. Clinical Chemistry and Laboratory Medicine, 48, 603–607.PubMedCrossRef
Zurück zum Zitat Mattsson, N., Johansson, P., Hansson, O., Wallin, A., Johansson, J. O., Andreasson, U., et al. (2010b). Converging pathways of chromogranin and amyloid metabolism in the brain. Journal of Alzheimers Disease, 20, 1039–1049. Mattsson, N., Johansson, P., Hansson, O., Wallin, A., Johansson, J. O., Andreasson, U., et al. (2010b). Converging pathways of chromogranin and amyloid metabolism in the brain. Journal of Alzheimers Disease, 20, 1039–1049.
Zurück zum Zitat Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., et al. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA, 302, 385–393.PubMedCrossRef Mattsson, N., Zetterberg, H., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., et al. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA, 302, 385–393.PubMedCrossRef
Zurück zum Zitat McKeith, I. G. (2006). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Journal of Alzheimers Disease, 9, 417–423. McKeith, I. G. (2006). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Journal of Alzheimers Disease, 9, 417–423.
Zurück zum Zitat McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939–944.PubMed McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939–944.PubMed
Zurück zum Zitat Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., et al. (1998). Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology, 51, 1546–1554.PubMed Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., et al. (1998). Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology, 51, 1546–1554.PubMed
Zurück zum Zitat Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F. E., Nagren, K., et al. (2009). Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology, 73, 754–760.PubMedCrossRef Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F. E., Nagren, K., et al. (2009). Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology, 73, 754–760.PubMedCrossRef
Zurück zum Zitat Olson, L., & Humpel, C. (2010). Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer’s disease and mild cognitive impairment. Experimental Gerontology, 45, 41–46.PubMedCrossRef Olson, L., & Humpel, C. (2010). Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer’s disease and mild cognitive impairment. Experimental Gerontology, 45, 41–46.PubMedCrossRef
Zurück zum Zitat Perry, V. H., Nicoll, J. A., & Holmes, C. (2010). Microglia in neurodegenerative disease. Nature Reviews Neurology, 6, 193–201.PubMedCrossRef Perry, V. H., Nicoll, J. A., & Holmes, C. (2010). Microglia in neurodegenerative disease. Nature Reviews Neurology, 6, 193–201.PubMedCrossRef
Zurück zum Zitat Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine, 256, 183–194.PubMedCrossRef Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine, 256, 183–194.PubMedCrossRef
Zurück zum Zitat Piras, I., Melis, A., Ghiani, M. E., Falchi, A., Luiselli, D., Moral, P., et al. (2007). Human CHIT1 gene distribution: New data from Mediterranean and European populations. Journal of Human Genetics, 52, 110–116.PubMedCrossRef Piras, I., Melis, A., Ghiani, M. E., Falchi, A., Luiselli, D., Moral, P., et al. (2007). Human CHIT1 gene distribution: New data from Mediterranean and European populations. Journal of Human Genetics, 52, 110–116.PubMedCrossRef
Zurück zum Zitat Renkema, G. H., Boot, R. G., Au, F. L., Donker-Koopman, W. E., Strijland, A., Muijsers, A. O., et al. (1998). Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. European Journal of Biochemistry, 251, 504–509.PubMedCrossRef Renkema, G. H., Boot, R. G., Au, F. L., Donker-Koopman, W. E., Strijland, A., Muijsers, A. O., et al. (1998). Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. European Journal of Biochemistry, 251, 504–509.PubMedCrossRef
Zurück zum Zitat Roman, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., et al. (1993). Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43, 250–260.PubMed Roman, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., et al. (1993). Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43, 250–260.PubMed
Zurück zum Zitat Schiffmann, R., Heyes, M. P., Aerts, J. M., Dambrosia, J. M., Patterson, M. C., DeGraba, T., et al. (1997). Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s disease. Annals of Neurology, 42, 613–621.PubMedCrossRef Schiffmann, R., Heyes, M. P., Aerts, J. M., Dambrosia, J. M., Patterson, M. C., DeGraba, T., et al. (1997). Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s disease. Annals of Neurology, 42, 613–621.PubMedCrossRef
Zurück zum Zitat Semple, B. D., Kossmann, T., & Morganti-Kossmann, M. C. (2010). Role of chemokines in CNS health and pathology: A focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. Journal of Cerebral Blood Flow and Metabolism, 30, 459–473.PubMedCrossRef Semple, B. D., Kossmann, T., & Morganti-Kossmann, M. C. (2010). Role of chemokines in CNS health and pathology: A focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. Journal of Cerebral Blood Flow and Metabolism, 30, 459–473.PubMedCrossRef
Zurück zum Zitat Sotgiu, S., Barone, R., Arru, G., Fois, M. L., Pugliatti, M., Sanna, A., et al. (2006). Intrathecal chitotriosidase and the outcome of multiple sclerosis. Multiple Sclerosis, 12, 551–557.PubMedCrossRef Sotgiu, S., Barone, R., Arru, G., Fois, M. L., Pugliatti, M., Sanna, A., et al. (2006). Intrathecal chitotriosidase and the outcome of multiple sclerosis. Multiple Sclerosis, 12, 551–557.PubMedCrossRef
Zurück zum Zitat Sotgiu, S., Piras, M. R., Barone, R., Arru, G., Fois, M. L., Rosati, G., et al. (2007). Chitotriosidase and Alzheimer’s disease. Current Alzheimer Research, 4, 295–296.PubMedCrossRef Sotgiu, S., Piras, M. R., Barone, R., Arru, G., Fois, M. L., Rosati, G., et al. (2007). Chitotriosidase and Alzheimer’s disease. Current Alzheimer Research, 4, 295–296.PubMedCrossRef
Zurück zum Zitat Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010). A meta-analysis of cytokines in Alzheimer’s disease. Biological Psychiatry, 68, 930–941.PubMedCrossRef Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010). A meta-analysis of cytokines in Alzheimer’s disease. Biological Psychiatry, 68, 930–941.PubMedCrossRef
Zurück zum Zitat van Eijk, M., Voorn-Brouwer, T., Scheij, S. S., Verhoeven, A. J., Boot, R. G., & Aerts, J. M. (2010). Curdlan-mediated regulation of human phagocyte-specific chitotriosidase. FEBS Letters, 584, 3165–3169.PubMedCrossRef van Eijk, M., Voorn-Brouwer, T., Scheij, S. S., Verhoeven, A. J., Boot, R. G., & Aerts, J. M. (2010). Curdlan-mediated regulation of human phagocyte-specific chitotriosidase. FEBS Letters, 584, 3165–3169.PubMedCrossRef
Metadaten
Titel
Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility
verfasst von
Niklas Mattsson
Shahrzad Tabatabaei
Per Johansson
Oskar Hansson
Ulf Andreasson
Jan-Eric Månsson
Jan-Ove Johansson
Bob Olsson
Anders Wallin
Johan Svensson
Kaj Blennow
Henrik Zetterberg
Publikationsdatum
01.06.2011
Verlag
Humana Press Inc
Erschienen in
NeuroMolecular Medicine / Ausgabe 2/2011
Print ISSN: 1535-1084
Elektronische ISSN: 1559-1174
DOI
https://doi.org/10.1007/s12017-011-8147-9

Weitere Artikel der Ausgabe 2/2011

NeuroMolecular Medicine 2/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.